Author
Listed:
- Rosa Andres-Ejarque
(Kings College London)
- Hira Bahadur Ale
(Kings College London)
- Katarzyna Grys
(Kings College London
Guys & St Thomas NHS Foundation Trust & King’s College London)
- Isabella Tosi
(Kings College London
Guys & St Thomas NHS Foundation Trust & King’s College London)
- Shane Solanky
(Kings College London)
- Chrysanthi Ainali
(Kings College London
DIGNOSIS Limited)
- Zeynep Catak
(Kings College London
Guys & St Thomas NHS Foundation Trust & King’s College London)
- Hemawtee Sreeneebus
(Kings College London
Guys & St Thomas NHS Foundation Trust & King’s College London)
- Jake Saklatvala
(Kings College London)
- Nick Dand
(Kings College London)
- Emanuele de Rinaldis
(Guys & St Thomas NHS Foundation Trust & King’s College London
Sanofi)
- Anna Chapman
(Lewisham and Greenwich NHS Trust)
- Frank O. Nestle
(Kings College London
Guys & St Thomas NHS Foundation Trust & King’s College London
Sanofi)
- Michael R. Barnes
(Queen Mary University of London, Charterhouse Square)
- Richard B. Warren
(Manchester Academic Health Science Centre)
- Nick J. Reynolds
(Institute of Translational and Clinical Medicine, Newcastle University Medical School and Department of Dermatology, Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust)
- Christopher E. M. Griffiths
(Manchester Academic Health Science Centre)
- Jonathan N. Barker
(Kings College London
Guys & St Thomas NHS Foundation Trust & King’s College London)
- Catherine H. Smith
(Kings College London
Guys & St Thomas NHS Foundation Trust & King’s College London)
- Paola Di Meglio
(Kings College London
Guys & St Thomas NHS Foundation Trust & King’s College London)
Abstract
No abstract is available for this item.
Suggested Citation
Rosa Andres-Ejarque & Hira Bahadur Ale & Katarzyna Grys & Isabella Tosi & Shane Solanky & Chrysanthi Ainali & Zeynep Catak & Hemawtee Sreeneebus & Jake Saklatvala & Nick Dand & Emanuele de Rinaldis & , 2021.
"Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis,"
Nature Communications, Nature, vol. 12(1), pages 1-1, December.
Handle:
RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-27447-6
DOI: 10.1038/s41467-021-27447-6
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-27447-6. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.